newsfilter
← Latest News
GlobeNewswire·

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R